Article ID | Journal | Published Year | Pages | File Type |
---|---|---|---|---|
2849021 | American Heart Journal | 2008 | 8 Pages |
Abstract
Despite weight-adjusted dosing, female patients reached higher anti-Xa levels, suggesting increased sensitivity to dalteparin treatment. Healthy women and female patients also had higher coagulation activity, which might increase the risk of thrombus formation. The large proportion of patients with subtherapeutic anti-Xa during prolonged dalteparin treatment may reflect poor compliance and could thus contribute to the gradual loss of clinical efficacy.
Related Topics
Health Sciences
Medicine and Dentistry
Cardiology and Cardiovascular Medicine
Authors
Jonas MD, PhD, Nina MD, PhD, Agneta MD, PhD,